ImmunityBio (IBRX) Net Income towards Common Stockholders (2014 - 2026)

ImmunityBio (IBRX) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$632.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 388.01% year-over-year to -$632.8 million; the TTM figure through Mar 2026 stood at -$854.6 million (down 108.86% YoY), while the FY2025 annual figure was -$351.5 million, up 15.03% from the prior year.
• Net Income towards Common Stockholders declined to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$59.2 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 74.65% — and 2026, when it tumbled 388.01%.
• ImmunityBio's Net Income towards Common Stockholders stood at -$108.3 million in 2022, then tumbled by 115.47% to -$233.4 million in 2023, then jumped by 74.65% to -$59.2 million in 2024, then retreated by 4.7% to -$62.0 million in 2025, then slumped by 921.32% to -$632.8 million in 2026.
• Business Quant data shows IBRX's Net Income towards Common Stockholders at -$632.8 million in Q1 2026, -$62.0 million in Q4 2025, and -$67.3 million in Q3 2025.